TargetMol

Sivopixant

Product Code:
 
TAR-T40045
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T40045-1mg1mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T40045-5mg5mg£340.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T40045-1mL1 mL * 10 mM (in DMSO)£405.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T40045-10mg10mg£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T40045-25mg25mg£707.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T40045-50mg50mg£978.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T40045-100mg100mg£1,291.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Sivopixant (S-600918) is a potent and selective antagonist of P2X3 receptor (P2X3 IC 50 =4.2 nM; P2X2/3 IC 50 =1100 nM). Sivopixant shows strong analgesic effect .
CAS:
2414285-40-6
Formula:
C25H22ClN5O5
Molecular Weight:
507.93
Pathway:
Membrane transporter/Ion channel; Neuroscience
Purity:
0.98
SMILES:
C[C@@H](CN(C(N/C(/N1Cc(cc2)ccc2Cl)=Nc(cc2)ccc2Oc2ncccc2)=O)C1=O)C(O)=O
Target:
P2X Receptor

References

Wang D P, Zhang M, Li M, et al.Druggable site near the upper vestibule determines the high affinity and P2X3 homotrimer selectivity of Sivopixant/S?600918 and its analogue DDTPA.British Journal of Pharmacology.2023 Kai H, et al. Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists [published online ahead of print, 2021 Sep 26]. Bioorg Med Chem Lett. 2021;52:128384.